Therapeutic effect of Echinococcus granulosus cyst fluid on bacterial sepsis in mice.
Cyst fluid
Echinococcus granulosus
Immunomodulation
Macrophage
Sepsis
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
08 Dec 2023
08 Dec 2023
Historique:
received:
07
08
2023
accepted:
18
10
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
The primary pathophysiological process of sepsis is to stimulate a massive release of inflammatory mediators to trigger systemic inflammatory response syndrome (SIRS), the major cause of multi-organ dysfunction and death. Like other helminths, Echinococcus granulosus induces host immunomodulation. We sought to determine whether E. granulosus cyst fluid (EgCF) displays a therapeutic effect on sepsis-induced inflammation and tissue damage in a mouse model. The anti-inflammatory effects of EgCF were determined by in vitro culture with bone marrow-derived macrophages (BMDMs) and in vivo treatment of BALB/C mice with cecal ligation and puncture (CLP)-induced sepsis. The macrophage phenotypes were determined by flow cytometry, and the levels of cytokines in cell supernatants or in sera of mice were measured (ELISA). The therapeutic effect of EgCF on sepsis was evaluated by observing the survival rates of mice for 72 h after CLP, and the pathological injury to the liver, kidney, and lung was measured under a microscope. The expression of TLR-2/MyD88 in tissues was measured by western blot to determine whether TLR-2/MyD88 is involved in the sepsis-induced inflammatory signaling pathway. In vitro culture with BMDMs showed that EgCF promoted macrophage polarization to M2 type and inhibited lipopolysaccharide (LPS)-induced M1 macrophages. EgCF treatment provided significant therapeutic effects on CLP-induced sepsis in mice, with increased survival rates and alleviation of tissue injury. The EgCF conferred therapeutic efficacy was associated with upregulated anti-inflammatory cytokines (IL-10 and TGF-β) and reduced pro-inflammatory cytokines (TNF-α and INF-γ). Treatment with EgCF induced Arg-1-expressed M2, and inhibited iNOS-expressed M1 macrophages. The expression of TLR-2 and MyD88 in EgCF-treated mice was reduced. The results demonstrated that EgCF confers a therapeutic effect on sepsis by inhibiting the production of pro-inflammatory cytokines and inducing regulatory cytokines. The anti-inflammatory effect of EgCF is carried out possibly through inducing macrophage polarization from pro-inflammatory M1 to regulatory M2 phenotype to reduce excessive inflammation of sepsis and subsequent multi-organ damage. The role of EgCF in regulating macrophage polarization may be achieved by inhibiting the TLR2/MyD88 signaling pathway.
Sections du résumé
BACKGROUND
BACKGROUND
The primary pathophysiological process of sepsis is to stimulate a massive release of inflammatory mediators to trigger systemic inflammatory response syndrome (SIRS), the major cause of multi-organ dysfunction and death. Like other helminths, Echinococcus granulosus induces host immunomodulation. We sought to determine whether E. granulosus cyst fluid (EgCF) displays a therapeutic effect on sepsis-induced inflammation and tissue damage in a mouse model.
METHODS
METHODS
The anti-inflammatory effects of EgCF were determined by in vitro culture with bone marrow-derived macrophages (BMDMs) and in vivo treatment of BALB/C mice with cecal ligation and puncture (CLP)-induced sepsis. The macrophage phenotypes were determined by flow cytometry, and the levels of cytokines in cell supernatants or in sera of mice were measured (ELISA). The therapeutic effect of EgCF on sepsis was evaluated by observing the survival rates of mice for 72 h after CLP, and the pathological injury to the liver, kidney, and lung was measured under a microscope. The expression of TLR-2/MyD88 in tissues was measured by western blot to determine whether TLR-2/MyD88 is involved in the sepsis-induced inflammatory signaling pathway.
RESULTS
RESULTS
In vitro culture with BMDMs showed that EgCF promoted macrophage polarization to M2 type and inhibited lipopolysaccharide (LPS)-induced M1 macrophages. EgCF treatment provided significant therapeutic effects on CLP-induced sepsis in mice, with increased survival rates and alleviation of tissue injury. The EgCF conferred therapeutic efficacy was associated with upregulated anti-inflammatory cytokines (IL-10 and TGF-β) and reduced pro-inflammatory cytokines (TNF-α and INF-γ). Treatment with EgCF induced Arg-1-expressed M2, and inhibited iNOS-expressed M1 macrophages. The expression of TLR-2 and MyD88 in EgCF-treated mice was reduced.
CONCLUSIONS
CONCLUSIONS
The results demonstrated that EgCF confers a therapeutic effect on sepsis by inhibiting the production of pro-inflammatory cytokines and inducing regulatory cytokines. The anti-inflammatory effect of EgCF is carried out possibly through inducing macrophage polarization from pro-inflammatory M1 to regulatory M2 phenotype to reduce excessive inflammation of sepsis and subsequent multi-organ damage. The role of EgCF in regulating macrophage polarization may be achieved by inhibiting the TLR2/MyD88 signaling pathway.
Identifiants
pubmed: 38066526
doi: 10.1186/s13071-023-06021-7
pii: 10.1186/s13071-023-06021-7
pmc: PMC10709918
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
450Subventions
Organisme : the Major Projects of Wuxi Municipal Health and Wellness Commission
ID : Z202114
Organisme : 512 Talents Development Project of Bengbu Medical College
ID : by51201306
Organisme : 512 Talents Development Project of Bengbu Medical College
ID : by51201205
Organisme : the Support Program for Excellent Talents in Higher Educational Institutions in Anhui Province
ID : gxyq2021188
Organisme : the Key Projects of Scientific Research of Anhui Provincial Health and Wellness Commission
ID : AHWJ2021a005
Informations de copyright
© 2023. The Author(s).
Références
Front Pharmacol. 2019 Oct 23;10:1255
pubmed: 31708781
Int Immunopharmacol. 2022 Aug;109:108907
pubmed: 35691271
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Ann N Y Acad Sci. 2012 Jan;1247:83-96
pubmed: 22239614
BMC Nephrol. 2019 Jun 17;20(1):223
pubmed: 31208365
Adv Ther. 2017 Nov;34(11):2393-2411
pubmed: 29022217
Med Sci Monit. 2019 Oct 22;25:7928-7935
pubmed: 31639817
Int Rev Immunol. 2014 Nov-Dec;33(6):498-510
pubmed: 24611785
Hypertension. 2014 Apr;63(4):663-4
pubmed: 24396026
Front Immunol. 2017 Apr 24;8:453
pubmed: 28484453
Front Cell Infect Microbiol. 2021 Mar 24;11:653843
pubmed: 33842398
mBio. 2021 Dec 21;12(6):e0271021
pubmed: 34749531
Immunol Res. 2015 Mar;61(3):312-25
pubmed: 25616617
J Physiol. 2010 Apr 15;588(Pt 8):1333-47
pubmed: 20176631
Pathog Dis. 2013 Nov;69(2):127-41
pubmed: 23929557
Exp Parasitol. 2019 Mar;198:63-70
pubmed: 30763570
Acta Trop. 2017 Feb;166:7-15
pubmed: 27983971
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Aug;32(8):1055-9
pubmed: 27412936
Crit Care. 2019 Jan 18;23(1):18
pubmed: 30658667
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
Autoimmun Rev. 2016 Jan;15(1):1-8
pubmed: 26299984
PLoS Pathog. 2016 Apr 21;12(4):e1005480
pubmed: 27101372
Immunobiology. 2007;212(6):475-90
pubmed: 17544832
Inflamm Res. 2016 Aug;65(8):587-602
pubmed: 26995266
Methods Mol Biol. 2019;1960:249-255
pubmed: 30798538
Trends Parasitol. 2008 Jan;24(1):35-42
pubmed: 18055264
Nat Rev Immunol. 2017 Apr;17(4):233-247
pubmed: 28192415
Immunol Res. 2012 Apr;52(1-2):111-9
pubmed: 22392054
Intensive Care Med. 2015 Sep;41(9):1620-8
pubmed: 26109396
Br Med Bull. 2017 Dec 01;124(1):121-133
pubmed: 29253150
Vascul Pharmacol. 2005 Nov;43(5):357-63
pubmed: 16271517
J Immunol. 2017 Oct 1;199(7):2191-2193
pubmed: 28923980
PLoS One. 2012;7(5):e37584
pubmed: 22655058
Crit Care. 2007;11(2):R49
pubmed: 17448250
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2021 Aug 23;33(6):655-659
pubmed: 35128902
Circulation. 2007 Nov 6;116(19):2127-38
pubmed: 17967775
Front Immunol. 2019 Oct 30;10:2536
pubmed: 31736963
Parasite Immunol. 2012 Nov;34(11):520-7
pubmed: 22803774
Shock. 2004 May;21(5):484-91
pubmed: 15087827
Inflamm Bowel Dis. 2005 May;11(5):515
pubmed: 15867596
Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62
pubmed: 12209125
Mol Cell Biochem. 2021 Jun;476(6):2337-2344
pubmed: 33586093
Monoclon Antib Immunodiagn Immunother. 2021 Feb;40(1):6-10
pubmed: 33347385
N Engl J Med. 2013 Aug 29;369(9):840-51
pubmed: 23984731
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):864-9
pubmed: 27559759
BMJ. 1989 Nov 18;299(6710):1259-60
pubmed: 2513902
Nat Immunol. 2013 Jan;14(1):52-60
pubmed: 23160153
Front Immunol. 2019 Jan 31;10:55
pubmed: 30766533
Parasit Vectors. 2014 Nov 20;7:522
pubmed: 25409540
Shock. 2012 Aug;38(3):227-42
pubmed: 22777111
Trends Immunol. 2009 Feb;30(2):75-82
pubmed: 19138565
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Parasit Vectors. 2017 May 8;10(1):222
pubmed: 28482922
Connect Tissue Res. 1991;26(4):271-81
pubmed: 1660802
Int Immunopharmacol. 2020 Dec;89(Pt B):107087
pubmed: 33075714
Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2772-80
pubmed: 16043850
J Inflamm (Lond). 2015 Mar 17;12:19
pubmed: 25844068
Int Endod J. 2023 Oct;56(10):1270-1283
pubmed: 37461231
Pharmacol Res. 2019 Aug;146:104292
pubmed: 31167111
J Interferon Cytokine Res. 2013 Sep;33(9):467-84
pubmed: 23675778
J Biomed Biotechnol. 2010;2010:743758
pubmed: 20169100
In Vivo. 2013 Nov-Dec;27(6):669-84
pubmed: 24292568
Inflamm Res. 2019 Jun;68(6):471-479
pubmed: 30927050
Inflammation. 2023 Dec;46(6):2276-2288
pubmed: 37606850
Int Immunopharmacol. 2018 May;58:173-185
pubmed: 29625385
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2022 Apr 8;34(2):194-199
pubmed: 35537844
Cell Res. 2013 Feb;23(2):201-12
pubmed: 23318584
Mol Cell Biochem. 2019 Feb;452(1-2):187-197
pubmed: 30178273